Summary:
A Randomized, Double-Blind, Multi-Center, Parallel Group, Chronic Dosing Study to Assess the Efficacy and Safety of PT009 compared to PT005, PT008, and Open-label Symbicort® Turbuhaler® as an Active Control on Lung Function over a 24-Week Treatment Period in Subjects with Moderate to Very Severe COPD
Qualified Participants Must:
• Be 40 years of age or older
•
Have a smoking history
Qualified Participants May Receive:
Study related care and possible reimbusement for travel